Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-1051 in Advanced Solid Tumors
NCT06260514Phase 1Recruiting
- Sponsor
- Aprea Therapeutics
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APR-1051 in solid tumor, sponsored by Aprea Therapeutics. Primary endpoints: Treatment-related adverse events and Recommended dose of APR-1051. Started Jun 2024; status: recruiting.
02
Drugs
APR-1051
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06260514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260514.